Evaluation of Bedside Methods to Measure Muscularity in Critically Ill Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03019913|
Recruitment Status : Completed
First Posted : January 13, 2017
Last Update Posted : March 27, 2019
Muscle wasting is a significant problem in critically ill patients, with reported losses of a half to three percent per day over the first ten days (for an average 70kg person this equates to 3 to 20kg of muscle loss). Low skeletal muscle mass at admission to the intensive care unit (ICU) and the loss of lean tissue have been associated with negative clinical outcomes, including increased incidence of infections, length of stay, mortality and muscle weakness. It is therefore crucial that technology is utilised to: 1) identify ICU patients with low muscularity on admission, 2) to help understand the factors impacting muscle loss and to 3) assess the effectiveness of interventions aimed at maintaining skeletal muscle mass in this population.
The measurement of lean body mass in patients admitted to the ICU is challenging however, due to the large fluid shifts that occur in this population and logistical issues in moving patients to specialised machinery for body composition analysis. Currently, there is no validated method for accurately assessing a patient's muscle mass at the bedside in the intensive care setting. It is therefore important to investigate the accuracy, feasibility and reliability of bedside methods such as subjective physical assessment of muscle mass, mid arm muscle circumference, ultrasound and bioimpedance analysis to assess muscularity in this population who are primarily bedbound. In order to do this, a critical comparison is required between these methods and muscularity assessed by a "reference" body composition method, such computed tomography (CT) image analysis. Briefly, quantification of skeletal muscle at the abdomen area utilising abdominal CT images has been shown to be highly representative of whole body skeletal muscle volume.
We wish to conduct a pilot, feasibility study (n= 50), which will recruit patients who have a CT scan (containing abdomen area), performed for clinical purposes. Our primary aim will be to investigate whether muscularity assessed with non-invasive bedside methods (ultrasound, bioimpedance analysis, SGA physical assessment, mid arm muscle circumference) are correlated with skeletal muscle mass quantified by a "reference method" (CT image analysis).
|Condition or disease||Intervention/treatment|
|Critical Illness||Other: Observational cohort|
Aim Our primary aim is to investigate whether muscularity assessed via bedside ultrasound is correlated with a reference method for estimating whole body skeletal muscle mass (CT image analysis) in the first few days of critical illness.
Our secondary aims are
- To investigate whether muscularity assessed via other bedside methods (bioimpedance spectroscopy, subjective physical assessment and mid arm muscle circumference) are correlated with a reference method for estimating whole body skeletal muscle mass (CT image analysis) in critically ill patients.
- To better understand the association between measured resting energy expenditure and muscularity in the critically ill.
- To observe changes in skeletal muscle mass (in a sub set of patients who have two CT scans) and the impact various factors, including energy and protein delivery has on these changes.
|Study Type :||Observational|
|Actual Enrollment :||50 participants|
|Official Title:||Evaluation of Bedside Methods to Measure Muscularity in Critically Ill Patients: A Prospective Observational Study|
|Study Start Date :||January 2017|
|Actual Primary Completion Date :||March 2019|
|Actual Study Completion Date :||March 2019|
- Other: Observational cohort
Evaluation of bedside methods to measure muscularity in critically ill patients
- Mean skeletal muscle mass measured by CT scan analysis at L3 area (cm2) [ Time Frame: CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission ]
- Mean skeletal muscle mass measured by ultrasound (muscle thickness at each site, cm and rectus femoris CSA, cm2) [ Time Frame: <48 hours after CT scan containing L3 area ]
- Fat free mass (kg), phase angle and impedance ratio measured by bioimpedance spectroscopy [ Time Frame: <48 hours after CT scan containing L3 area ]
- Subjective assessment of muscle and fat wasting via SGA (normal, mild-moderate or severe) [ Time Frame: <48 hours after CT scan containing L3 area ]
- Mid arm muscle circumference (cm) [ Time Frame: <48 hours after CT scan containing L3 area ]
- Mean skeletal muscle mass measured by CT scan analysis at femoral area (cm2) [ Time Frame: CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission ]
- Measured resting energy expenditure (kilojoules) [ Time Frame: <48 hours after CT scan containing L3 area ]
- Intramuscular, subcutaneous and visceral adipose tissue CSA at L3 area (cm2) [ Time Frame: CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03019913
|The Alfred Hospital|
|Melbourne, Victoria, Australia, 3004|
|Principal Investigator:||Kate Lambell, MNutrDiet||La Trobe University and Alfred Health|